Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 18 January 2018, 09:30 HKT/SGT
Share:
    

Source: Eisai
Eisai: Patent Infringement Litigation for Antiemetic Agent ALOXI in the United States

TOKYO, Jan 18, 2018 - (JCN Newswire) - Eisai has announced today that the United States Court of Appeals for the Federal Circuit, in the patent infringement lawsuit for antiemetic agent ALOXI (palonosetron hydrochloride) injection brought by Helsinn Healthcare S.A. against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. in the United States, has denied Helsinn's petition for rehearing en banc, which if granted would have allowed the full court to review a panel decision issued in May 2017, that certain formulation patent claims covering ALOXI are not valid and are therefore not infringed by Teva's generic palonosetron product.

On May 1, 2017, a panel of the Federal Circuit issued a decision that reversed the opinion of the District Court for the District of New Jersey and held that the asserted claims for the ALOXI formulation patents are not valid and therefore not infringed by Teva's generic palonosetron product. In response to this decision, Helsinn filed a petition for rehearing en banc, asking for a review of the panel decision by all eligible judges. During this process, amicus briefs (opinions from third parties) supporting the position of Helsinn and Eisai were submitted to the Federal Circuit by Congressman Lamar Smith, who co-drafted the America Invents Act, the Pharmaceutical Research and Manufacturers of America (PhRMA), the American Intellectual Property Law Association (AIPLA), the Biotechnology Innovation Organization (BIO), the Boston Patent Law Association (BPLA) and the Intellectual Property Owners /Association (IPO).

However, Helsinn's petition was denied. Helsinn will file for a stay of the mandate at the Federal Circuit and, if necessary, at the Supreme Court. Furthermore, Helsinn will continue to explore all legal options available to protect the ALOXI patents, including requesting review by the US Supreme Court. Additional patents covering the product exist, which were not included in the Federal Circuit's prior decision and which will continue to be litigated at the New Jersey District Court.

Teva will not be able to launch a generic version of ALOXI until additional steps are taken by the Federal Circuit, the District Court for the District of New Jersey and the Food & Drug Administration (FDA) allowing such a launch.

Helsinn and Eisai are disappointed with the court's ruling. Protecting intellectual property is vital to a company's ability to continue developing innovative medicines. Helsinn and Eisai maintain their position that the patents protecting ALOXI are valid and will pursue further legal options to protect and enforce such patents.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology.

In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com

About Eisai and the Helsinn Group

Eisai Inc. gained exclusive marketing rights to ALOXI in the United States and Canada from Helsinn Healthcare S.A. through its acquisition of MGI Pharma, Inc. in 2008. Under the terms of the agreement, Helsinn Healthcare S.A. is responsible for conducting all development activities (Chemistry and Manufacturing Controls (CMC), preclinical and clinical), obtaining regulatory approvals and holding the New Drug Application (NDA). ALOXI is co-promoted in the United States by Eisai Inc. and Helsinn Therapeutics U.S. Inc., while sales of the product in the United States are booked by Eisai Inc.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Jan 18, 2018 09:30 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Jan 22, 2019 16:54 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time
Jan 18, 2019 13:33 HKT/SGT
Eisai's Notification Regarding Results of Voluntary Retirement Program
Jan 15, 2019 13:31 HKT/SGT
Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium
Jan 15, 2019 13:23 HKT/SGT
Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
Jan 4, 2019 11:18 HKT/SGT
Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards
Jan 4, 2019 08:39 HKT/SGT
Eisai's New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration
Dec 18, 2018 10:38 HKT/SGT
Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform
Dec 17, 2018 08:21 HKT/SGT
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Brazil with Eurofarma
Dec 12, 2018 09:06 HKT/SGT
GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics
Dec 6, 2018 09:24 HKT/SGT
Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: